Moleculin Biotech (NASDAQ:MBRX) Earns “Buy” Rating from HC Wainwright

Moleculin Biotech (NASDAQ:MBRX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $22.00 price objective on the stock.

Several other analysts have also recently issued reports on MBRX. Roth Mkm restated a “buy” rating on shares of Moleculin Biotech in a report on Monday, December 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $22.00.

Moleculin Biotech Stock Performance

NASDAQ:MBRX opened at $2.49 on Tuesday. Moleculin Biotech has a one year low of $1.79 and a one year high of $28.75. The stock has a market cap of $5.08 million, a PE ratio of -0.08 and a beta of 1.73. The stock has a 50 day moving average price of $3.29 and a 200 day moving average price of $6.91.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC purchased a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech as of its most recent SEC filing. Institutional investors own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.